|
MechanismChemerin receptors modulators [+2] |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Multicenter, Double-Masked, Parallel-Group, Vehicle-Controlled Study to Assess the Efficacy and Safety of RX-10045 Nanomicellar Ophthalmic Solution for Treatment of Ocular Inflammation and Pain in Subjects Undergoing Cataract Surgery
The primary objective of this study is to assess the efficacy and safety of 2 concentrations of RX-10045 ophthalmic solution, 0.05% and 0.1%, compared to placebo for the treatment of ocular inflammation and pain in subjects undergoing cataract surgery.
100 Clinical Results associated with A.T. Resolve SARL
0 Patents (Medical) associated with A.T. Resolve SARL
100 Deals associated with A.T. Resolve SARL
100 Translational Medicine associated with A.T. Resolve SARL